ClinicalTrials.gg
RecruitingNCT05640453Updated Jun 25, 2025

Pregabalin Versus Dexmedetomidine for Delirium Treatment After Coronary Artery Bypass Grafting

A Phase 4 interventional study of Pregabalin and Dexmedetomidine in Pregabalin, Delirium Treatment and Coronary Artery Bypass Grafting, sponsored by Tanta University. Recruiting at 1 site in Egypt. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-06-25.

Sponsored by Tanta University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Dec 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies testing dexmedetomidine in Delirium — 14 open to participants now, 17 under way, 4 of them phase 3. Dexmedetomidine · Delirium.

Planned enrollment
46th of 78
70 · median 98
Started
2022
with 6 others
Phase 4
35 of 78
5 open now
Primary completion
2026-05
later than 5 of 16 live
Registered
65th of 78
by date
Lead sponsor
4 of 78
Tanta University

Among the 78 studies testing dexmedetomidine in Delirium, this one is the 46th largest by planned enrollment, is one of 7 that started in 2022, is one of 35 in phase 4, reaches primary completion later than 5 of the 16 other live ones, and was the 65th registered.

Delirium

935 studies on the registry are indexed under Delirium; 188 are open to participants now.

Browse Delirium studies →

Open to participants now

14 of the 78 studies testing dexmedetomidine in Delirium are open now, in 5 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About dexmedetomidine

Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 124 Delirium studies recruiting now, 96 (77%) set no upper age limit and 8 (6%) stop at 75 or younger; 8 take children under 18; 14 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies testing dexmedetomidine in Delirium, or all of them as a file.
02

Study summary

The aim of this study is to determine the effect of pregabalin versus dexmedetomidine on the treatment and lasting duration of delirium in fast tracking elderly patients after Coronary Artery Bypass Grafting.

Read the detailed description

Delirium is an acute brain disorder that involves changes in consciousness, attention, cognition, and perception.The incidence of postoperative delirium (POD) is high among patients undergoing cardiac surgery, ranging from 20 to 50%, and the risk is even higher in the elderly.

03

Conditions studied

  • Pregabalin
  • Delirium Treatment
  • Coronary Artery Bypass Grafting
  • Dexmedetomidine

Browse trials for

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • CABG patients ≥ 65 years of age both genders (ASA) physical status classification II or III planned for fast track developed postoperative delirium (POD).

Exclusion criteria

Exclusion Criteria:

  • Patients who had history of psychiatric diseases; inability to communicate;
  • previous history of POD; preoperative sick sinus syndrome, allergy/sensitivity to pregabalin or dexmedetomidine, severe bradycardia (heart rate \<50 beat per minute), second-degree or above atrioventricular block without pacemaker; severe hepatic or renal insufficiency.
  • Previous cardiac or thoracic surgery, known diagnosis of depression or other major psychiatric diseases, cognitive impairment or inability to cooperate with the study, renal insufficiency, and history of substance abuse.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Active comparator
    Pregabalin group

    Patients will receive pregabalin capsules (75 mg) every 12 h for 24 hours by nasogastric tube.

    Drug: Pregabalin

  • Active comparator
    Dexmedetomidine group

    Patients will receive a bolus dose of 0.4 μg/kg dexmedetomidine (over a period of 10 to 20 min) followed by an infusion of 0.2 to 0.7 μg/h.

    Drug: Dexmedetomidine

Interventions

  • Patients will receive pregabalin capsules (75 mg) every 12 h for 24 hours by nasogastric tube.

  • Patients will receive a bolus dose of 0.4 μg/kg dexmedetomidine (over a period of 10 to 20 min)

06

What researchers measure

Primary outcomes

  1. Percent of delirium treatment

    Assessment of delirium will be performed preoperatively and postoperatively at 12-h intervals or as needed according to the patient's condition using the confusion assessment method (CAM)

    Time frame: 24 hour postoperatively

Secondary outcomes

  1. Level of sedation

    Sedation level will be assessed by using the Ramsey sedation scale.

    Time frame: 24 hour postoperatively

  2. Incidence of weaning from mechanical ventilation

    percent of patients who weaned from mechanical ventilation

    Time frame: 1 week postoperatively

  3. Length of hospital stay

    Time frame: 1 month postoperatively

07

Study locations

1 of 1 sites recruiting
  • Islam Morsy
    Tanta, El-Gharbia Governorate, Egypt
    Recruiting
    • Islam Morsy, MD · Contacteslam.morsy@med.tanta.edu.eg · 00201093387374
    • Mohammed S El Sharkawy, MD · Sub investigator
    • Hussein G Almawardy, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — The data will available upon reasonable request from the principal investigator

Supporting information: Study protocol, Statistical analysis plan

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for May 2026, 41 months after the start.

Of 40 non-industry phase 4 interventional studies under Delirium, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 62. This study's planned 41 months is close to that.

Counting every sponsor, half of 40 studies reached it within 44 months; a quarter within 25 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2022
First posted
Dec 7, 2022
StartActual
Dec 15, 2022
Primary completionEst.
May 15, 2026
CompletionEst.
May 15, 2026
Last update
Jun 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05640453
Lead sponsor
Tanta University
Responsible party
Islam Morsy (Lecturer of Anesthesiology, Surgical Intensive Care and Pain Medicine, Tanta University) — Principal investigator
First posted
Dec 7, 2022
Start date
Dec 15, 2022
Primary completion
May 15, 2026 (estimated)
Completion
May 15, 2026 (estimated)
Last update
Jun 25, 2025

Study contacts

Islam Morsy, MD
Contact
eslam.morsy@med.tanta.edu.eg
00201093387374

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pregabalin · Dexmedetomidine

Start the discussion